Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide in children with achondroplasia (extension study)
NCT03424018Phase 3Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Dec 2017
- Primary completion
- Jun 2031
- Modality
- Peptides
- Countries
- 7
01
Overview
A Phase 3 trial of vosoritide in achondroplasia (ACH), sponsored by BioMarin Pharmaceutical. Started Dec 2017; status: active, not recruiting.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT03424018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03424018.